• 1
    American Heart Association, Overweight and Obesity Statistics - 2009 Update. 2009
  • 2
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303: 235-41.
  • 3
    Pickering G. High Blood Pressure. New York, NY: Grune and Stratton, Inc. 1968.
  • 4
    Kannel WB, Brand N, Skinner JJ, Jr., Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967; 67: 48-59.
  • 5
    Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956; 4: 20-34.
  • 6
    Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed). 1984; 289: 1257-61.
  • 7
    Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984; 288: 1401-4.
  • 8
    Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol. 1990; 1: 33-48.
  • 9
    Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982; 54: 254-60.
  • 10
    Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983; 72: 1150-62.
  • 11
    Kalkhoff RK, Hartz AH, Rupley D, Kissebah AH, Kelber S. Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med. 1983; 102: 621-7.
  • 12
    Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317: 350-7.
  • 13
    Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985; 75: 809-17.
  • 14
    Landsberg L. The metabolic syndrome: diabetes, obesity and hypertension. In: Surya P, ed.Handbook of Hypertension. Hypertension in the Twentieth Century: Concepts and Achievements. USA: Press; 2004; 22: 245-61.
  • 15
    Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001; 19( 3Pt2): 523-8.
  • 16
    Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta JA, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981; 30: 219-25.
  • 17
    Hausberg M, Mark AL, Hoffman RP, Sinkey CA, Anderson EA. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens. 1995; 13: 1015-21.
  • 18
    Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991; 17: 669-77.
  • 19
    Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995; 25: 560-3.
  • 20
    Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994; 89: 2634-40.
  • 21
    Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998; 97: 2037-42.
  • 22
    DeFronzo RA. Insulin and renal sodium handling: clinical implications. International Journal of Obesity. 1981; 5 suppl 1: 93-104.
  • 23
    Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1997; 82: 1293-300.
  • 24
    Tang-Christensen M, Havel PJ, Jacobs RR, Larsen PJ, Cameron JL. Central administration of leptin inhibits food intake and activates the sympathetic nervous system in rhesus macaques. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 711-7.
  • 25
    Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997; 100: 270-8.
  • 26
    Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine. 1999; 130: 671-80.
  • 27
    Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998; 31: 409-14.
  • 28
    Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997; 46: 2040-3.
  • 29
    Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, et al. High plasma immunoreactive leptin level in essential hypertension. American Journal of Hypertension. 1997; 10( 10Pt1): 1171-4.
  • 30
    Kazumi T, Kawaguchi A, Katoh J, Iwahashi M, Yoshino G. Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. Journal of Hypertension. 1999; 17: 1451-5.
  • 31
    Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Quarterly Journal of Medicine. 1986; 61: 1081-90.
  • 32
    Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005; 45: 356-62.
  • 33
    Goodfriend TL. Obesity, sleep apnea, aldosterone, and hypertension. Curr Hypertens Rep. 2008; 10: 222-6.
  • 34
    Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Journal of Hypertension. 2008; 26: 831-43.
  • 35
    Bomback AS, Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. American Journal of Nephrology. 2009; 30: 140-6.
  • 36
    Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2009; 5: 101-11.
  • 37
    Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005; 46: 1316-20.
  • 38
    Hall JE, Guyton AC, Coleman TG, Mizelle HL, Woods LL. Regulation of arterial pressure: role of pressure natriuresis and diuresis. Federation Proceedings. 1986; 45: 2897-903.
  • 39
    Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. New England Journal of Medicine. 1989; 321: 580-5.
  • 40
    Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. American Journal of Hypertension. 2003; 16: 72-5.
  • 41
    Van Cauter E SK. Sleep as a mediator of the relationship between socioeconomic status and health: A hypothesis. Annals NY Acad Sci. 1999; 896: 254-61.
  • 42
    Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiologica Scandinavica. 2003; 177: 385-90.
  • 43
    Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003; 42: 1067-74.
  • 44
    Spiegel K, Leproult R, L'Hermite-Baleriaux M, Copinschi G, Penev PD, Van Cauter E. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004; 89: 5762-71.
  • 45
    Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab. 2002; 13: 364-8.
  • 46
    Silverman BL, Landsberg L, Metzger BE. Fetal hyperinsulinism in offspring of diabetic mothers. Association with the subsequent development of childhood obesity. Annals of the New York Academy of Sciences. 1993; 699: 36-45.
  • 47
    Hausberg M, Barenbrock M, Kosch M. Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome? Journal of Hypertension. 2004; 22: 1087-9.
  • 48
    Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Research. 2003; 11: 1278-89.
  • 49
    Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009; 52: 752-64.
  • 50
    Gillespie C, Kuklina EV, Briss PA, Blair NA, Hong Y. Vital Signs: Prevalence, treatment, and control of hypertension: United States, 1999-2002 and 2005-2008. MMWR - Morbidity & Mortality Weekly Report. 2011; 60: 103-8.
  • 51
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Disease and Stroke Statistics-2011 Update: A Report From the American Heart Association. Circulation. 2011; 123: e18-209.
  • 52
    Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines. Arch Intern Med. 2004; 164: 2126-34.
  • 53
    Wilson PWF, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162: 1867-72.
  • 54
    Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25: 305-13.
  • 55
    Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96: 308-15.
  • 56
    Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L, Loria CM, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007; 115: 1004-11.
  • 57
    Mamun AA, Lawlor DA, O'Callaghan MJ, Williams GM, Najman JM. Effect of Body Mass Index Changes Between Ages 5 and 14 on Blood Pressure at Age 14: Findings From a Birth Cohort Study. Hypertension. 2005; 45: 1083-7.
  • 58
    Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-13.
  • 59
    Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, NY: Raven Press; 1995: 127-44.
  • 60
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598-615.
  • 61
    Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005; 294: 466-72.
  • 62
    Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Wilson PW, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Archives of Internal Medicine. 1999; 159: 2206-12.
  • 63
    D'Agostino RB, Grundy SM, Sullivan LM, Wilson P, Group ftCRP. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286: 180-7.
  • 64
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 8:983-8.
  • 65
    Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006; 37: 345-50.
  • 66
    Wolf P, D'Agostino R, Belanger A, Kannel W. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22: 312-8.
  • 67
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002; 106: 3068-72.
  • 68
    Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275: 1557-62.
  • 69
    Hsu C-y, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney Disease. Arch Intern Med. 2005; 165: 923-8.
  • 70
    Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144: 21-8.
  • 71
    Stamler J, Dyer AR, Shekelle RB, Neaton JD, Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology. 1993; 82: 191-222.
  • 72
    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58.
  • 73
    Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet. 1998; 351: 1755-62.
  • 74
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 1998; 339: 229-34.
  • 75
    Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005; 28: 2901-7.
  • 76
    Hansen BC, Bray GA. The Metabolic Syndrome Epidemiology, Clinical Treatment, and Underlying Mechanisms. Totowa, NJ: Humana Press, 2008.
  • 77
    Reaven GM. Metabolic Syndrome To Be or Not to Be? In: B. C. Hansen, G. A. Bray eds. The Metabolic Syndrome Epidemiology, Clinical Treatment, and Underlying Mechanisms. Totowa, NJ: Humana Press, 2008: 11-36.
  • 78
    Ervin R. Prevalence of Metabolic Syndrome Among Adults 20 Years of Age and Over, by Sex, Age, Race and Ethnicity, and Body Mass Index: United States, 2003-2006. National Health Statistics Reports. 2009; 13: 1-8.
  • 79
    Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109: 433-8.
  • 80
    Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007; 292: F423-9.
  • 81
    Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47: 962-7.
  • 82
    Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. American Journal of Clinical Nutrition. 2007; 86: 899-906.
  • 83
    Choi Jea. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008; 59: 109-16.
  • 84
    Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999; 354: 1435-9.
  • 85
    Bass J, Turek FW. Sleepless in America: a pathway to obesity and the metabolic syndrome? Archives of Internal Medicine. 2005; 165: 15-6.
  • 86
    Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005; 308: 1043-5.
  • 87
    Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Penev PD. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010; 153: 435-41.
  • 88
    l'Allemand-Jander D. Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child. Int J Obes (Lond). 2010; 34 Suppl 2: S32-6.
  • 89
    Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: the Bogalusa Heart Study. Hypertension. 2006; 48: 33-9.
  • 90
    Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011; 365: 1876-85.
  • 91
    Craigie AM, Lake AA, Kelly SA, Adamson AJ, Mathers JC. Tracking of obesity-related behaviours from childhood to adulthood: A systematic review. Maturitas. 2011; 70: 266-84.
  • 92
    Eriksson J, Forsen T, Tuomilehto J, Osmond C, Barker D. Fetal and childhood growth and hypertension in adult life. Hypertension. 2000; 36: 790-4.
  • 93
    Huang RC, Mori TA, Burke V, Newnham J, Stanley FJ, Landau LI, et al. Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents. Diabetes Care. 2009; 32: 695-701.
  • 94
    Huang RC, Burke V, Newnham JP, Stanley FJ, Kendall GE, Landau LI, et al. Perinatal and childhood origins of cardiovascular disease. Int J Obes (Lond). 2007; 31: 236-44.
  • 95
    Chivers PT, Hands B, Parker H, Beilin LJ, Kendall GE, Bulsara M.. Longitudinal modelling of body mass index from birth to 14 years. Obesity Facts. 2000; 2: 302-10.
  • 96
    Waters E, de Silva-Sanigorski A, Hall BJ, Brown T, Campbell KJ, Gao Y, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev. 2011; 12: 00.
  • 97
    Vandongen R, Jenner DA, Thompson C, Taggart AC, Spickett EE, Burke V, et al. A controlled evaluation of a fitness and nutrition intervention program on cardiovascular health in 10- to 12-year-old children. Prev Med. 1995; 24: 9-22.
  • 98
    Burke V, Milligan RA, Thompson C, Taggart AC, Dunbar DL, Spencer MJ, et al. A controlled trial of health promotion programs in 11-year-olds using physical activity “enrichment” for higher risk children. J Pediatr. 1998; 132: 840-8.
  • 99
    Milligan RA, Thompson C, Vandongen R, Beilin LJ, Burke V. Clustering of cardiovascular risk factors in Australian adolescents: association with dietary excesses and deficiencies. J Cardiovasc Risk. 1995; 2: 515-23.
  • 100
    Taylor BJ, Heath AL, Galland BC, Gray AR, Lawrence JA, Sayers RM, et al. Prevention of Overweight in Infancy ( study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth. BMC Public Health. 2011; 11: 942.
  • 101
    Berenson GS. Cardiovascular health promotion for children: a model for a Parish (County)-wide program (implementation and preliminary results). Prev Cardiol. 2010; 13: 23-8.
  • 102
    Sobko T, Svensson V, Ek A, Ekstedt M, Karlsson H, Johansson E, et al. A randomised controlled trial for overweight and obese parents to prevent childhood obesity-Early STOPP (Stockholm Obesity Prevention Program) BMC Public Health. 2011; 11: 336.
  • 103
    Christie D, Hudson L, Mathiot A, Cole TJ, Karlsen S, Kessel A, et al. Assessing the efficacy of the healthy eating and lifestyle programme (HELP) compared with enhanced standard care of the obese adolescent in the community: study protocol for a randomized controlled trial. Trials. 2011; 12: 242.
  • 104
    Borys JM, Le Bodo Y, Jebb SA, Seidell JC, Summerbell C, Richard D, et al. EPODE approach for childhood obesity prevention: methods, progress and international development. Obes Rev. 2011; 13: 299-315.
  • 105
    Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011; 364: 2392-404.
  • 106
    Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007; 29: 6-28.
  • 107
    Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2011; 70: 3-21.
  • 108
    Zhai F, Wang H, Wang Z, Popkin BM, Chen C. Closing the energy gap to prevent weight gain in China. Obes Rev. 2008; 9 Suppl 1: 107-12.
  • 109
    Akers JD, Estabrooks PA, Davy BM. Translational research: bridging the gap between long-term weight loss maintenance research and practice. J Am Diet Assoc. 2010; 110: 1511-22
  • 110
    Anderson SE, Whitaker RC. Prevalence of obesity among US preschool children in different racial and ethnic groups. Arch Pediatr Adolesc Med. 2009; 163: 344-8.
  • 111
    Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003; 42: 878-84.
  • 112
    Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005; 45: 1035-41.
  • 113
    Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension. 2009; 54: 756-62.
  • 114
    Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011; 9: CD008274.
  • 115
    Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab. 2008; 93( 11Suppl1): S81-8.
  • 116
    Makris A, Foster GD. Dietary approaches to the treatment of obesity. Psychiatr Clin North Am. 2011; 34: 813-27.
  • 117
    Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004; 8: iii-iv.
  • 118
    Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr., Brehm BJ, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166: 285-93.
  • 119
    Appel LJ. ASH position paper: Dietary approaches to lower blood pressure. J Am Soc Hypertens. 2009; 3: 321-31.
  • 120
    Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997; 336: 1117-24.
  • 121
    **Joint National Committee on Prevention E, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: US Department of Health and Human Services; 2004.
  • 122
    Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011; 57: 1299-313.
  • 123
    Beilin LJ, Burke V. Vegetarian diet components, protein and blood pressure: which nutrients are important? Clin Exp Pharmacol Physiol. 1995; 22: 195-8.
  • 124
    Miller ER, 3rd, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension. 2002; 40: 612-8.
  • 125
    Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006; 144: 485-95.
  • 126
    Jehn ML, Patt MR, Appel LJ, Miller ER, 3rd. One year follow-up of overweight and obese hypertensive adults following intensive lifestyle therapy. J Hum Nutr Diet. 2006; 19: 349-54.
  • 127
    Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007; 50: 609-16.
  • 128
    Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010; 170: 126-35.
  • 129
    Gao SK, Fitzpatrick AL, Psaty B, Jiang R, Post W, Cutler J, et al. Suboptimal nutritional intake for hypertension control in 4 ethnic groups. Arch Intern Med. 2009; 169: 702-7.
  • 130
    Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. J Hypertens. 2005; 23: 1241-9.
  • 131
    Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344: 3-10.
  • 132
    Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010; 55: 813-8.
  • 133
    Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007; 334: 885-8.
  • 134
    Surya P. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Hypertension Prevention Trial Research Group. Arch Intern Med. 1990; 150: 153-62.
  • 135
    Whelton PK, Kumanyika SK, Cook NR, Cutler JA, Borhani NO, Hennekens CH, et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr. 1997; 65( 2 Suppl): 652S-60S.
  • 136
    Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001; 134: 1-11.
  • 137
    Kumanyika SK, Cook NR, Cutler JA, Belden L, Brewer A, Cohen JD, et al. Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens. 2005; 19: 33-45.
  • 138
    Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001; 161: 685-93.
  • 139
    Thorogood A, Mottillo S, Shimony A, Filion KB, Joseph L, Genest J, et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med. 2011; 124: 747-55.
  • 140
    Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005; 29: 1153-67.
  • 141
    Fagard RH. Exercise is good for your blood pressure: effects of endurance training and resistance training. Clin Exp Pharmacol Physiol. 2006; 33: 853-6.
  • 142
    Cox KL, Puddey IB, Morton AR, Burke V, Beilin LJ, McAleer M. Exercise and weight control in sedentary overweight men: effects on clinic and ambulatory blood pressure. J Hypertens. 1996; 14: 779-90.
  • 143
    Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011; 58: 950-8.
  • 144
    Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006; 00: CD003817.
  • 145
    Fogelholm M, Kukkonen-Harjula K. Does physical activity prevent weight gain-a systematic review. Obes Rev. 2000; 1: 95-111.
  • 146
    Jakicic JM. The effect of physical activity on body weight. Obesity (Silver Spring). 2009; 17 Suppl 3: S34-8.
  • 147
    Proper KI, Singh AS, van Mechelen W, Chinapaw MJ. Sedentary behaviors and health outcomes among adults: a systematic review of prospective studies. Am J Prev Med. 2011; 40: 174-82.
  • 148
    Puddey IB, Beilin LJ. Alcohol is bad for blood pressure. Clin Exp Pharmacol Physiol. 2006; 33: 847-52.
  • 149
    Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G. Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis. Eur J Epidemiol. 2011; 26: 833-50.
  • 150
    Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutr Rev. 2011; 69: 419-31.
  • 151
    Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992; 20: 533-41.
  • 152
    Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res. 2005; 13: 1466-75.
  • 153
    Rhee MY, Na SH, Kim YK, Lee MM, Kim HY. Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension. Am J Hypertens. 2007; 20: 637-41.
  • 154
    Simpson SA, Shaw C, McNamara R. What is the most effective way to maintain weight loss in adults? BMJ. 2011; 343: d8042.
  • 155
    Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity. Med Clin North Am. 2011; 95: 971-88.
  • 156
    Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011; 11: 119.
  • 157
    Svetkey LP, Stevens VJ, Brantley PJ, Appel LJ, Hollis JF, Loria CM, et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008; 299: 1139-48.
  • 158
    Funk KL, Stevens VJ, Appel LJ, Bauck A, Brantley PJ, Champagne CM, et al. Associations of internet website use with weight change in a long-term weight loss maintenance program. J Med Internet Res. 2010; 12: e29.
  • 159
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine. 2001; 344: 1343-50.
  • 160
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
  • 161
    McCullough ML, Patel AV, Kushi LH, Patel R, Willett WC, Doyle C, et al. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiology, Biomarkers and Prevention. 2011; 20: 1089-97.
  • 162
    Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Annals of Medicine. 2000; 32: 239-51.
  • 163
    Angermayr L, Melchart D, Linde K. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus-a systematic review of randomized controlled trials. Annals of Behavioral Medicine. 2010; 40: 49-64.
  • 164
    Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011; 00: 00.
  • 165
    Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and or the European Society of Cardiology (ESC). European Heart Journal. 2007; 28: 1462-536.
  • 166
    Moore LL, Visioni AJ, Qureshi MM, Bradlee ML, Ellison RC, D'Agostino R. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med. 2005; 165: 1298-303.
  • 167
    Allcock DM, Sowers JR. Best strategies for hypertension management in type 2 diabetes and obesity. Curr Diab Rep. 2010; 10: 139-44.
  • 168
    Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005; 23: 463-73.
  • 169
    Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006; 1: 29-35.
  • 170
    Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002; 20: 1879-86.
  • 171
    Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008; 31: 982-8.
  • 172
    Lardizabal JA, Deedwania PC. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr Cardiol Rep. 2010; 12: 464-71.
  • 173
    Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-92.
  • 174
    Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008; 26: 1891-900.
  • 175
    Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006; 24: 1405-12.
  • 176
    Grimm C, Koberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess. 2010; 6: Doc03.
  • 177
    **National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung and Blood Institute (US). 2004; Report No.: 04-5230.
  • 178
    Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011; 35: 1395-403.
  • 179
    Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007; 120: 610-5.
  • 180
    Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001; 37: 250-4.
  • 181
    Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009; 11: 309-15.
  • 182
    NHLBI Obesity Education Initiative Working Group. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: NIH Publication; 2000.
  • 183
    Lawrence CB, Turnbull AV, Rothwell NJ. Hypothalamic control of feeding. Curr Opin Neurobiol. 1999; 9: 778-83.
  • 184
    Garfield AS, Lam DD, Marston OJ, Przydzial MJ, Heisler LK. Role of central melanocortin pathways in energy homeostasis. Trends Endocrinol Metab. 2009; 20: 203-15.
  • 185
    van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, et al. Cold-activated brown adipose tissue in healthy men. New England Journal of Medicine. 2009; 360: 1500-8.
  • 186
    Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481: 463-8.
  • 187
    Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012; 122: 1022-36.
  • 188
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27: 155-61.
  • 189
    Genentech USA, Inc. South San Francisco, CA: Xenical (Orlistat) Package Insert. December 2010.
  • 190
    Surya P. Over-the-counter weight loss with orlistat? Drug Ther Bull. 2009; 47: 125-7.
  • 191
    Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000; 9: 160-7.
  • 192
    Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000; 8: 49-61.
  • 193
    Kaplan LM. Pharmacological therapies for obesity. Gastroenterol Clin North Am. 2005; 34: 91-104.
  • 194
    Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005; 142: 532-46.
  • 195
    Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007; 132: 2239-52.
  • 196
    Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002; 26: 262-73.
  • 197
    Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011; 19: 2351-60.
  • 198
    Bristol-Myers Squibb Company, Uxbridge, Uk: Glucophage (metformin) package insert. 2009.
  • 199
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995; 333: 541-9.
  • 200
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998; 21: 701-5.
  • 201
    Amylin Pharmaceuticals and Eli Lilly & Company. Byetta Package Insert. Cincinnati Ohio: Amylin Pharmaceuticals and Eli Lilly & Company; 2010.
  • 202
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30: 1448-60.
  • 203
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-100.
  • 204
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-35.
  • 205
    Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-91.
  • 206
    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8: 436-47.
  • 207
    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007; 29: 139-53.
  • 208
    Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33: 1759-65.
  • 209
    Amylin Pharmacueticals. Symlin (pramlintide) Package Insert. 812003-CC. Cincinnati Ohio: Amylin Pharmacueticals; 2008.
  • 210
    Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004; 21: 1204-12.
  • 211
    Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011; 12: 1439-51.
  • 212
    Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26: 784-90.
  • 213
    Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007; 92: 2977-83.
  • 214
    Aronne LJ, Isoldi KK, Roarke DT. The Johns Hopkins University Textbook of Dyslipidemia Chapter 24: Therapeutic Options for Modifying Obesity and Cardiometabolic Risk Factors. 288.
  • 215
    Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008; 31: 1816-23.
  • 216
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 1341-52.
  • 217
    Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376: 595-605.
  • 218
    Rubino F, R'Bibo S L, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol. 2010; 6: 102-9.
  • 219
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724-37.
  • 220
    Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351: 2683-93.
  • 221
    Delling L, Karason K, Olbers T, Sjostrom D, Wahlstrand B, Carlsson B, et al. Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial. J Obes. 2010; 102341.
  • 222
    Saxe JS. Promoting healthy lifestyles and decreasing childhood obesity: increasing physician effectiveness through advocacy. Ann Fam Med. 2011; 9: 546-8.